心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JCO：癌症不同，心血管疾病风险不同

2016-02-08 MedSci译 MedSci原创

心血管疾病癌症
关注

 据估计，美国现如今有一千四百万癌症幸存者，到2024年这一数字将达到一千九百万。在这些癌症幸存者中，三分之二已经在癌症诊断后存活了超过五年，每五个幸存者中有两个被认为可以存活达到十年。这也直接导致了癌症患病人群的老龄化。目前，心血管疾病已经成为了主要的导致发病率和死亡率的原因。对于儿童以及年龄在四十岁以下的年轻人被诊断为癌症的患者，心血管疾病，包括缺血性心脏病、卒中和心衰其与癌症治疗相

据估计，美国现如今有一千四百万癌症幸存者，到2024年这一数字将达到一千九百万。在这些癌症幸存者中，三分之二已经在癌症诊断后存活了超过五年，每五个幸存者中有两个被认为可以存活达到十年。这也直接导致了癌症患病人群的老龄化。目前，心血管疾病已经成为了主要的导致发病率和死亡率的原因。对于儿童以及年龄在四十岁以下的年轻人被诊断为癌症的患者，心血管疾病，包括缺血性心脏病、卒中和心衰其与癌症治疗相关的迟发效应的联系已经被完整地揭示。但是对于年龄超过四十岁的成年癌症患者，长期幸存后与心血管疾病相关的迟发效应尚不清晰。

研究人员进行了一项回顾性队列研究。在一个大型的综合管理医疗组织中，研究人员匹配了两个队列，第一个是36232名超过两年的成年癌症幸存者，另一个队列为非癌症对照组（73545人）。使用多变量回归来检验心血管风险因素（高血压、糖尿病、血脂异常）对癌症幸存者长期心血管疾病风险的影响。多发性骨髓瘤、肺癌、非霍奇金淋巴瘤以及乳腺癌的幸存者相对于非癌症对照组有着更高的心血管疾病风险。与此相反，前列腺癌患者心血管疾病风险低于对照组。有着两个或更多的心血管风险因素的癌症患者有着最高的心血管疾病风险。患有心血管疾病的癌症患者的八年总生存率显著低于其他癌症幸存者。

此项研究表明，不同癌症亚型以及患者自身心血管风险因素数量的多少影响着心血管疾病风险。这说明针对不同亚型的癌症，其预防心血管疾病的策略也大不相同。

原始出处：
Armenian S H, Xu L, Ky B, et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study[J]. Journal of Clinical Oncology, 2016: JCO640409.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891251, encodeId=247e189125105, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu May 26 20:15:00 CST 2016, time=2016-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64177, encodeId=050c641e7e5, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Sat Feb 13 12:34:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472984, encodeId=d03414e2984c7, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Feb 10 06:15:00 CST 2016, time=2016-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497959, encodeId=76ea149e9599b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Feb 10 06:15:00 CST 2016, time=2016-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63811, encodeId=6e026381103, content=需要循证支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Feb 09 14:30:00 CST 2016, time=2016-02-09, status=1, ipAttribution=)]
    2016-05-26 lidong40

    #JCO#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1891251, encodeId=247e189125105, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu May 26 20:15:00 CST 2016, time=2016-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64177, encodeId=050c641e7e5, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Sat Feb 13 12:34:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472984, encodeId=d03414e2984c7, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Feb 10 06:15:00 CST 2016, time=2016-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497959, encodeId=76ea149e9599b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Feb 10 06:15:00 CST 2016, time=2016-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63811, encodeId=6e026381103, content=需要循证支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Feb 09 14:30:00 CST 2016, time=2016-02-09, status=1, ipAttribution=)]
    2016-02-13 lietome1

    赞

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1891251, encodeId=247e189125105, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu May 26 20:15:00 CST 2016, time=2016-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64177, encodeId=050c641e7e5, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Sat Feb 13 12:34:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472984, encodeId=d03414e2984c7, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Feb 10 06:15:00 CST 2016, time=2016-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497959, encodeId=76ea149e9599b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Feb 10 06:15:00 CST 2016, time=2016-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63811, encodeId=6e026381103, content=需要循证支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Feb 09 14:30:00 CST 2016, time=2016-02-09, status=1, ipAttribution=)]
    2016-02-10 花花1368

    #疾病风险#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1891251, encodeId=247e189125105, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu May 26 20:15:00 CST 2016, time=2016-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64177, encodeId=050c641e7e5, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Sat Feb 13 12:34:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472984, encodeId=d03414e2984c7, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Feb 10 06:15:00 CST 2016, time=2016-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497959, encodeId=76ea149e9599b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Feb 10 06:15:00 CST 2016, time=2016-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63811, encodeId=6e026381103, content=需要循证支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Feb 09 14:30:00 CST 2016, time=2016-02-09, status=1, ipAttribution=)]
    2016-02-10 andy2090

    #血管疾病#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1891251, encodeId=247e189125105, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu May 26 20:15:00 CST 2016, time=2016-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64177, encodeId=050c641e7e5, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Sat Feb 13 12:34:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472984, encodeId=d03414e2984c7, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Feb 10 06:15:00 CST 2016, time=2016-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497959, encodeId=76ea149e9599b, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Feb 10 06:15:00 CST 2016, time=2016-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63811, encodeId=6e026381103, content=需要循证支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Feb 09 14:30:00 CST 2016, time=2016-02-09, status=1, ipAttribution=)]
    2016-02-09 dhzzm

    需要循证支持

    0

相关资讯

Lancet Diabetes Endocrinol：中国早发糖尿病患者发生非致命的心血管疾病的风险增加

背景：2型糖尿病发病年龄降低。因为早发2型糖尿病非中国患者（这里定义为40岁以下的患者），血管并发症的风险增加，研究者调查了中国早发性和迟发性2型糖尿病对非致命的心血管疾病发生风险的影响。方法：研究者使用中国糖化血红蛋白监测系统数据调查（CNHSS）的数据进行横断面的调查研究，包括2012年中国30省106个城市630家医院2型糖尿病患者222 773名。研究者记录了人口学资料和临床资料。非致命性

BMJ：克拉霉素的使用增加了短期内心血管疾病的风险

克拉霉素的使用和心血管事件之间有什么联系呢？原始出处：Angel Y S Wong,Adrian Root,Ian J Douglas,et al.Cardiovascular outcomes associated with use of clarithromycin,BMJ,2016.1.14

BMJ Open：创伤后应激障碍与心血管疾病事件相关

目的：创伤后应激障碍（PTSD）是心血管疾病（CVD）的危险因素。然而，另一种常见的应激障碍调节障碍与心血管疾病的风险增加是否相关，以及这种相关是否存在性别差异。本研究的目的是调查创伤后应激障碍和及调节障碍和4个心血管事件之间的整体和性别分层的相关性。设计：利用丹麦国家注册数据的一项前瞻性队列研究。设置：丹麦总人口。参与者：1995到2011年间，创伤后应激障碍（n = 4724）和调节障碍（N

Atherosclerosis：阿利吉仑对糖尿病患者和非糖尿病患者的影响（AQUQRIUS）

背景：以前发现阿利吉仑在规定应用血管紧张素转换酶抑制剂（ACEI）或血管紧张素受体拮抗剂（ARB）糖尿病患者中存在潜在的有害影响。研究者探讨了阿利吉仑对糖尿病患者和非糖尿病患者冠状动脉粥样硬化的进展和主要不良心血管事件（MACE：死亡、非致死性心肌梗死、非致死性卒中或因心力衰竭住院、因ACS住院、动脉血运重建）的影响。方法：AQUQRIUS研究对冠脉疾病患者进行血管内超声检测冠状动脉硬化斑块的体积

ACE：论空中瑜伽的好处

空中瑜伽是瑜伽的一种,主要使用吊床而使得参与者身体抬离地面,使他们能够完成传统的瑜伽姿势,使健身者的身体可以在半空中舒展开来。但是它真的能起到锻炼效果么？科罗拉多大学的研究人员致力于探究空中瑜伽课程培训和六周空中瑜伽健身对民众健康的影响。 Cedric X. Bryant博士认为，尽管空中瑜伽不属于传统的有氧运动,但是它能提供的健身效果相当于民众进行了低-中等强度的有氧运动(如快走或慢速骑自行车）

BMJ：房颤是否是女性心血管疾病和死亡的较强风险因素？

该研究的目的是确定女性与男性相比，房颤是否是心血管疾病和死亡的较强的风险因素。原始出处：Connor A Emdin,Christopher X Wong,Allan J Hsiao,et al.Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men,BMJ